Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
PAAB eFiles Tag and CEI Report Q2 - 2023
-
Hello Forum Community
The Q2 Tag Report and the CEI Report are now available. Thank you to everyone who has participated in the CEIs thus far.
Take a look at some of the findings and let us know what else you'd like to know in the comments below.
Have a great week.
-
@jennifer-carroll Thanks for the reports, much appreciated! We were wondering if it would be possible for future reports to include some information about the dismissed tags? (e.g. what criteria they went against, what guideline they ignored etc) That way we could learn from our mistakes and potentially improve collaboration in the future
-
or maybe communicate directly to the tag submitter(s)?
-
@costeap Absolutely we can add guidance on why tags were deemed invalid. Great suggestion. We’ll add it in to Q3. Thank you for the feedback.
